Various bacterial membrane molecules are able to activate cells of the innate immune system in a non-specific fashion. Lipopolysaccharide (LPS) is a prototypic representative of such activators. LPS binds to the CD14-TLR4-MD2 cell surface receptor complex on monocytes/macrophages which is followed by a phosphorylation cascade that involves MyD88, IRAK, TRAF6, NIK, IKK and IκB (see Fig. 1 ). Phosphorylation of IκB initiates proteolytic degradation of this molecule such that the preformed p50p65 (i.e. the classical NF-κB) is released and can translocate into the nucleus where it binds to various promotors and leads to transactivation of the respective genes. There is a host of genes transactivated by NF-κB and all of these are activated after LPS stimulation. Among them is the prototypic pro-inflammatory cytokine TNF. TNF can activate the cells of the immune system which enhances the immune defence against the invading bacteria. Some of the activities of LPS like the activation of the coagulation system via activation of tissue factor and the action on the cardiovascular system may, however, be detrimental such that diffuse intravascular coagulation and hyperdynamic shock ensue.
Therefore, mechanisms to prevent this excessive production are required in order to ensure survival of the host. LPS tolerance (hyporesponsiveness, desensitization) is such a mechanism. LPS tolerance typically occurs when the innate immune system is exposed to LPS repeatedly which leads to strongly diminished secondary response, i.e. to no or only minimal production of TNF.
In tolerance that occurs as an essential immunological mechanism in antigen-specific B-cells and T-cells, there are 3 principal possibilities: (i) the respective cells are deleted; (ii) the respective cell surface receptors are downregulated; or (iii) the signal transduction is blocked.
In LPS tolerance, there is little evidence for deletion of monocytes/macrophages. Also, the CD14 cell surface receptor is not down-regulated. Rather, the major mechanism in LPS tolerance appears to operate in the signal transduction cascade.
Several reports have noted a lack of NF-κB mobilization. Depletion of the p65 NF-κB protein has been described. 1 An increase of IκBα has been noted in LPS tolerance in heart tissue.
2 Also, LPS tolerance was found to be associated with reduced IKK activity. 3 In a study by Li et al., depletion of IRAK and a failure of the remaining IRAK to interact with MyD88 was observed. 4 The most membrane proximal mechanism was reported by the Akira group. 5 These authors noted a reduced binding of an antibody that recognizes the TLR4/MD2 complex in mice. Whether this is due to a down-regulation of either TLR4 or MD2 or whether it reflects a dissociation of the two molecules remains to be studied. To date, this report is, however, the only one that implies receptor down-regulation as a possible mechanism of LPS tolerance.
Additional signalling mechanisms have been reported to be impaired in LPS tolerance. These include a decrease in the activity of small GTP-binding proteins 6 and a decrease in the activity of MAP kinases. [7] [8] [9] These signalling pathways may well feed into cascades that regulate expression of the TNF gene but their exact role is still ill-defined.
There is an entirely different mechanism of LPS tolerance that we discovered a few years ago. It is based on the phenomenon that in tolerant monocytes there is an increase in the NF-κB p50 protein. 10 This p50 accumulates in the cell and forms homodimers which can bind to GGGACTTTCCC NF-κB sequences, while it shows little binding to less palindromic sequences that carry only CC at the 3′ end, e.g. GGGACTTTCCG.
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In contrast to the RelA (p65), RelB and c-rel members of the rel-NF-κB family, p50 does not carry a transactivation domain. Hence, when the p50p50 homodimer binds to appropriate DNA sequences in different promotors it will not transactivate but will block access of heterodimers like p50p65. Therefore, binding of p50p50 will block transactivation by the classical NF-κB. This then leads to blockade of genes like TNF or iNOS (see Fig. 2) . 10, 12, 13 The p50p50 homodimer mechanism is initiated by p50p65 NF-κB upon the initial exposure of cells to LPS. This NF-κB binds to sequences in the promotor regulating the expression of p105, the precursor protein which is cleaved to give rise to p50. By contrast, the promotor for p65 (Rel-A) does not carry any NF-κB binding sites and, therefore, its expression is unaltered in LPS tolerance. This differential behaviour of p50 and p65 can also be demonstrated by Western blotting. Here, the total amount of p65 in cytoplasm is unaltered in LPS tolerance and p65 is also mobilized into the nucleus when tolerant cells are challenged with LPS. 12 At the same time, Western blots show that the p50 protein and its p105 precursor increase in the cytoplasm, and the p50 protein is also increased in the nucleus.
In order to demonstrate that excessive p50 protein can, in fact, block expression of the TNF gene, we have overexpressed p50 in the presence of p65 together with a TNF promotor luciferase reporter gene construct in HEK-293 cells. These studies clearly showed that p50 when present in high amounts will prevent transactivation of the TNF gene. 12 The reverse experiment is to delete p50 and to ask whether under such conditions the LPS tolerance is prevented. Studies by Bohuslav et al. 14 have shown that peritoneal macrophages from p50 -/-mice do not downregulate TNF mRNA and protein when exposed to LPS repeatedly. We have obtained similar data for TNF protein with spleen cells from p50 -/-mice (unpublished). Hence, it appears that the p50p50 homodimer blockade is indeed operative in LPS tolerance in man and mice.
There have been additional reports that support this view. Liu et al. noted an increase of p50p50 in gelshift after repeated LPS stimulation of RAW 264.7 mouse macrophages. 15 Similar data were recently provided by Fujihara et al. 16 The time of primary exposure is of importance for the p50p50 mechanism of LPS tolerance. Short periods of time in the range of hours are not sufficient. With this type of protocol, mechanisms like the reduction in IKK activity leading to the inability of NF-κB mobilization prevail. In order for the p50p50 mechanism to come into play, days are required for accumulation of the protein. This is nicely demonstrated in the study by Fujihara et al., which compares short and long primary LPS exposures for tolerance induction in side-by-side analysis with the P388D1 mouse macrophage cell line. 16 When the primary LPS exposure is 1 h, there is a blockade of IκBα phosphorylation and a blockade of NF-κB mobilization. By contrast, when the primary exposure is 2 days, NF-κB is mobilized but there is the predominance of p50p50. 16 At this late point in time, the short-term effects have disappeared and now p50p50 is responsible for tolerance.
This latter type of mechanism may have more general importance. We have noted that the p52 gene which is encoded in tandem with p50 can be responsible for LPS tolerance in a B-cell system. 17 Also, Laegreid et al. have shown that triggering the TNF receptor repeatedly can up-regulate p50 homodimers. 18 Also, in T-cell receptor transgenic mice, repeated stimulation with superantigen will up-regulate p50p50 leading to tolerance. 19 While TNF is the prototypic cytokine that is down-regulated in LPS tolerance, there are others that are less affected, like IL-6 or KC. 20 But there are also genes that are up-regulated in tolerance and that further increase with secondary stimulation, like IL-18, 20 and chemokines like IL-8 and MCP-1. 21 We speculate that these genes fail to be suppressed in LPS tolerance because their promotors cannot efficiently be blocked by the p50p50 mechanism. In fact, the NF-κB motifs in the promotors of both IL-8 and MCP-1 show only 2 cytosines at their 3′-ends. As noted above, this type of motif has only little binding affinity for p50 homodimers.
LPS tolerance does have clinical implications. Early on it was demonstrated that malaria patients with pyelonephritis or typhoid fever are tolerant to LPS. When these patients are challenged with LPS-containing vaccines a few days after resolution of fever, their febrile response is strongly diminished. [22] [23] [24] More recent studies in patients with severe infection, i.e. sepsis, have also demonstrated LPS tolerance. Production of TNF, IL-1 and IL-6 by monocytes or in whole blood was found to be dramatically reduced after in vitro stimulation with LPS. 25, 26 We have also speculated that the LPS tolerance induced by infection in vivo may also involve the p50p50 homodimer mechanisms. In fact, in an elegant study, AdibConquy et al. showed that PBMC from sepsis patients when stimulated by LPS mobilized NF-κB with a predominance of p50p50 in gelshift analysis. 27 Taken together, there is increasing evidence to indicate that blockade of gene expression by up-regulation of p50p50 homodimers is operative in LPS tolerance induced in model cell lines, in primary cells and in patients with severe infection.
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